A molecular jewel for hemophilia A treatment
Research output: Contribution to journal › Review article › peer-review
Colleges, School and Institutes
In this issue of Blood, Seth Chhabra et al describe the engineering of a new therapeutic chimera composed of B domain-deleted (BDD) factor VIII (FVIII), FVIII-binding domain of von Willebrand factor (VWF), Fcg1 fragment, and XTEN polypeptides.1 The molecule, referred to as rFVIIIFc-VWF-XTEN or BIVV001, has a prolonged half-life that is independent from endogenous VWF and is hemostatically competent.
|Number of pages||3|
|Publication status||Published - 23 Apr 2020|